EI
OCUL icon

EAM Investors’s Ocular Therapeutix OCUL Stock Holding History

EAM Investors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-224,211
Closed -$1.18M – 330
2023
Q1 		$1.18M Buy
+224,211
New +$1.06M 0.23% 211
2021
Q1 		– Sell
-292,722
Closed -$6.06M – 412
2020
Q4 		$6.06M Buy
292,722
+36,325
+14% +$539K 0.99% 5
2020
Q3 		$1.95M Sell
256,397
-89,678
-26% -$744K 0.46% 62
2020
Q2 		$2.88M Hold
346,075
– – 0.64% 30
2020
Q1 		$1.71M Buy
+346,075
New +$1.71M 0.53% 76

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

EAM Investors's OCUL Position: Q2 2023 in Review

EAM Investors sold out of Ocular Therapeutix (OCUL) in Q2 2023, closing a stake of 224,211 shares — an estimated $1.18M sold.

EAM Investors first reported a position in OCUL in Q1 2020 and held it in 5 quarters. The position peaked at $6.06M in Q4 2020. 135 funds tracked by Wall St. Rank hold OCUL as of Q2 2023.

  • EAM Investors reported no remaining Ocular Therapeutix position as of Q2 2023 after selling out during the quarter.
  • EAM Investors sold 224,211 Ocular Therapeutix shares in Q2 2023, an estimated $1.18M.
  • EAM Investors first reported a position in Ocular Therapeutix in Q1 2020 and held it in 5 quarters.
  • EAM Investors's Ocular Therapeutix position peaked at $6.06M in Q4 2020.
  • 135 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2023.

Based on EAM Investors's 13F filing for Q2 2023, filed 11 Aug 2023.